The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Chemotherapy induced peripheral neuropathy is a big problem in the management of many common cancers. In particular, taxane base regimens (used in breast and lung cancer), and oxaliplatin (used in colorectal cancers) have reasonable rates of peripheral neuropathy. While many patients...
We have a major probelm in our healthcare system, and it has to do with declining reimbursements and increasing overhead. Small physician practices are learning that the only way to remain competitive is to increase throughput of patients, thus shortening encounters, and dealing with fewer...
The data from the STAR P-2 trial on tamoxifen vs. raloxifene show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease. This very large trial...
IMC-A12 is a fully human IgG1Mab that is designed to specifically target the human insulin-like growth factor type 1 receptor, thereby inhibiting certain ligands known as insulin-like growth factors I and II from binding to and activating the receptor. This action blocks a signaling pathway that enhances...
Hematide provides a novel mechanism to increase hemoglobin by binding to the epo receptor. It is unclear yet if hematide lacks the similar safety issues of Aranesp, Procrit, and Epogen, and these studies will hopefully shed some light. The longer interval between doses (4 weeks) is attractive...
Continuous cuts in physician reimbursement along with rising practice overhead cost are eventually going to cost our health system's quality, and loss of access for patients.
New phase II data shows no benefit in time to progression, and likely signals no further investigation in this drug for ovarian cancer However, early data for NSCLC has been reported as promising, and, this could be a potential avenue of research and future market.
While the idea of a vaccine against cancer is elegant in theory and design, prior vaccine trials have been busts. Anecdotal stories always generate promise, but until it's proven in a randomized fashion, I won't believe the hype.
There are ways to control costs, reduce premiums and provide access to quality healthcare plans. Creativity in plan design and customization of plans are key areas insurers are exploring in order to meet the demands of current trends and to build and retain customer loyalty.
The controversy of contingent commissions is not a new one. This debate has caused significant changes to our views of broker payments, disclosure, ethics, and loyalty. The central question started off as being one about disclosure. Theoretically, if the client is aware then there isn't an issue. If...